Sareum, UCB collaborate on cancer drug discovery

By Lisa Kerner

Erie, Pa., Jan. 26 - Sareum Holdings plc said it has entered into a collaborative agreement with UCB to provide protein structure determination capabilities to accelerate UCB's cancer drug discovery research.

Under the agreement, Sareum will provide UCB with access to Sareum's Crystal Bank protein structures. Sareum will generate structures of selected proteins engaged with UCB's potential drug candidates, according to a company news release.

In return, Sareum will receive access fees and success milestone payments. Financial terms of the agreement were not disclosed.

Crystal Bank, a collection of protein targets, is a resource for clients requiring fast turnaround of structural data that shows how their compounds bind with selected protein targets, officials said.

"We are delighted that UCB has chosen Sareum as their partner in protein structure determination," Sareum chief executive officer Dr. Tim Mitchell said in the release.

"This is a further important collaboration that Sareum has signed with a global pharmaceutical company and an additional example of how our Crystal Bank protein structure resource is providing revenues to support our in-house drug discovery programs."

Sareum is a specialist structure-based drug discovery and services business with headquarters in Cambridge, England.

UCB is a global biopharmaceutical company with its headquarters in Brussels, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.